Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.

Ann Med · 2024 · PMC10878334 · PMID 38364218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In all groups, there was a decrease in mOCS especially in patients treated with mepolizumab, but differences did not reach statistical significance probably due to dispersion of the variables and the limited sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.